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BioinformaticsCancer cell differentiation is an important ﬁeld of discussion in the light of cancer stem cells. In a recent study by
Herr et al. (2015) “B-RAF inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells”we
described how inhibition of mutant BRAF in colorectal cancer cell lines induces cell re-differentiation that is cor-
relatedwith the loss of tumor growth in vitro and in vivo.We used IlluminaHumanHT-12 v4Expression BeadChip
to characterize the gain of differentiation of PLX4720-treated 3D cultures of HT29 and Colo-205 cells. Here, we
describe the experimental design and statistical analysis that were performed on the data set leading to the
above hypothesis. The data are publicly available at the Gene Expression Omnibus (GEO) database under the ac-
cession number GSE50791.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).SpeciﬁcationsOrganism/cell line/tissue Homo sapiens/colorectal cancer (CRC) cell lines HT29
and Colo-205Sex HT29 cells are derived from the primary tumor of a
44-year-old female CRC patient.
Colo-205 is a metastatic cell line derived from the
malignant ascites of a 70-year-old male CRC patient.Sequencer or array type Illumina HumanHT-12 v4 Expression BeadChip
Data format Raw and quantile normalized
Experimental factors I.e. tumor vs. normal, any pretreatment of samples
HT29 and Colo-205 cells were grown in
three-dimensional (3D) Matrigel culture in vitro and
treated with DMSO or the B-RAF inhibitor PLX4720.Experimental features We performed a time-resolvedmicroarray analysis of
PLX4720- versus DMSO-treated HT29 and Colo-205 3D
tissue cultures to determine differentially expressed tran-
scripts. Cellswere seeded intoMatrigel, cultivated for 4 days
and subsequently treated with DMSO or 3 μMPLX4720.
Cells were harvested at different time points, total RNAwas
isolated and Biotin-labeled cRNA samples were hybridized
on Illumina HumanHT-12 v4 Expression BeadChip.Consent Not applicable
Sample source location Not applicablelular Microenvironment Group,
. This is an open access article underDirect link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE50791.
Experimental design, materials and methods
Tissue culture
Three-dimensional (3D) cultures of the colon cancer cell lines
Colo-205 [2] (CLS Cell Lines Service GmbH, Heidelberg, Germany) and
HT29 [3] (kind gift of Prof. Dr. T. Brabletz, Erlangen, Germany) were
set-up as described previously [1,4]. In brief, 4-well chamber slides
(BD Biosciences) were coated with a thin layer of ice-cold Matrigel
(75 μl) and incubated at 37 °C for at least 30 min to allow solidiﬁcation
of the Matrigel. Subsequently, cells (3–5 × 103 cells/well) were resus-
pended in culture medium containing 2% Matrigel and seeded on top
of the solidiﬁed Matrigel. The Matrigel-supplemented medium was
replaced every 2–3 days.
Inhibitor treatment and cell extraction
HT29 and Colo-205 3D cultures were treated with DMSO or with
3 μM of the B-RAF inhibitor PLX4720 dissolved in DMSO 4 days after
seeding. Cells were harvested at three different time points after
starting the treatment: at 1, 3 and 8 days for HT29 and at 1,3 andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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lines required different experimental end time points. The HT29 sam-
ples were measured in duplicates. To extract the cells the medium
was aspirated and 500 μl recovery solution (BD Biosciences) were
added to each well. The cell/gel mixture was scraped into a 15 ml tube
using a pipette tip. Following 1 h of incubation on ice the cells were
washed twice with 15 ml ice-cold DPBS (centrifugation: 10 min,
1200 rpm, 4 °C) and the cell pellet used for total RNA isolation.
RNA isolation and microarray analysis
RNA was extracted using the Universal RNA Puriﬁcation Kit
(GeneMatrix) from Roboklon. RNA quality and integrity were veriﬁed
using the Agilent 2100 Bioanalyzer system (Agilent Technologies).
Biotin-labeled cRNA samples for hybridization on Illumina HumanHT-
12 v4 Expression BeadChip (Illumina, Inc.) were prepared according to
the Illumina's recommended sample labeling procedure. In brief,
250 ng total RNA was used for complementary DNA (cDNA) synthesis,
followed by an ampliﬁcation/labeling step (in vitro transcription) to
synthesize biotin-labeled cRNA according to the MessageAmp II aRNA
Ampliﬁcation kit (Ambion, Inc., Austin, TX). Quality of cRNA was con-
trolled using the RNA Nano Chip Assay on an Agilent 2100. Microarray
scanning was performed using a Beadstation array scanner, setting
adjusted to a scaling factor of 1 and PMT settings at 430. Data extraction
was done for all beads individually, and outliers are removedwhen N2.5
MAD (median absolute deviation). All remaining data points are used
for the calculation of the mean average signal for a given probe, and
standard deviation for each probe was calculated. All arrays were
quantile normalizedwithout background subtraction using the Illumina
BeadStudio software.
The Illumina probes were annotated with the custommappings from
the Bioconductor R package illuminaHumanv4.db [5]. Probes that were
ﬂagged as ‘bad’, i.e. matching repeat sequences, intergenic or intronic
regions, or having ‘No match’, i.e.without match for any genomic region
or transcript, according to the illuminaHumanv4PROBEQUALITY map-
ping were discarded. The remaining probes were annotated to the
EntrezIDs provided by the illuminaHumanv4ENTREZREANNOTATED
map. The ‘ﬁndLargest’ function from the R Bioconductor package
geneﬁlter [6] resolved the problem, if multiple probes matched the
same Entrez gene. The function ﬁnds all replicates and selects the one
with the largest interquartile rank (IQR) in expression across all samples,
ﬁnally retaining 19,178 Entrez genes in the Colo-205 and the HT29 array
samples.
RNA of both cell lines was hybridized to different Illumina bead
chips. After normalization there was amarked difference in the normal-
ized expression values (Fig. 1A). Due to the unknown contributions of
either technical or biological variability we restricted our analysis toA B
Fig. 1. Bead chip normalization and principal component analysis. (A) Boxplot of the quantile
Illumina Human-HT12 bead chips resulting in different gene expression distributions. (B, C) Pr
along theﬁrst principal component (PC1) result from gene expression changes due to 3D culture
results is conﬁrmed by the proximity of the HT29 sample duplicates.comparisons of within cell line differences with respect to treatment
and time. A principal component analysis (PCA) [7] on both cell line
samples (Fig. 1B and C) conﬁrmed 3D culture growth as the largest
inﬂuence on gene expression followed by the effect of PLX4720 treat-
ment, which showed in the separation along PC1 and PC2, and is
marked in the plots by ‘Culture’ and ‘Treatment’, respectively. Further-
more, the duplicates for the HT29 lie close to each other, which demon-
strates the reproducibility of the 3D culture.
Due to the similar PCA response patterns between Colo-205 and
HT29 we hypothesized that the culture conditions and treatment
might elicit similar genes. As we did not have replicate samples for the
Colo-205, we performed for both cell lines a moderated F-test using
the R ‘limma’ package [8] on the treatment versus control samples to
identify genes that responded differently over time. p-Values from the
F-statistic were corrected for false discovery rate estimation according
to Benjamini and Hochberg. There was a signiﬁcant Pearson correlation
of r= 0.71 for all differentially genes between PLX4720 and control in
both cell lines (adjusted p-value b0.001), supporting our initial hypoth-
esis. A hypergeometric test on the Biological Processes from the human
Gene Ontology using the R GOstats package [9] showed a strong
involvement of these genes in developmental and differentiation
processes (Fig. 2).
B-RAF inhibition leads to induction of differentiation
The above ﬁndings led to the assumption that the effect of PLX4720
reintroduced a differentiation phenotype from the otherwise more
stem cell like cancer phenotype. To corroborate in detail the loss of
stemness/pluripotency we used the PluriNet gene set [10] as marker
for the stemness or inversely the differentiation status of the cells. The
marker set consists of 299 genes that were derived from classifying
human pluripotent, multipotent and differentiated cells. To assess the
overall stemness/differentiation status of the Colo-205 and HT29 cells,
we compared the PluriNet gene expression among all NCI60 cell lines
[11]. Gene expression had been measured using the Affymetrix
Human Genome U133 Plus 2.0 arrays, which we normalized together
using robust multichip averaging [12] in conjunction with the custom
deﬁnition ﬁle from Brainarray in Version 17.0 [13]. A principal compo-
nent analysis separated the samples along the PC1 according to their
marker gene expression, predicting the acute lymphoblastic leukemia
cell line MOLT-4 as least and the ovary adenocarcinoma derived
SK-OV-3 as the most differentiated cells (Fig. 3A). The signiﬁcant
higher expression of the PluriNet marker genes in Colo-205 cells rel-
ative to HT29 (p-value b 10−10, one-sided t-test) likewise indicated a
higher stemness of the former (Fig. 3B). To assess the loss of stemness
we performed a gene set enrichment using the Generally Applicable
Gene-set Enrichment (GAGE) [14]. For analysis we performed anC
normalized gene expression data. Colo-205 and HT29 have been hybridized to different
incipal component analysis of the Colo-205 and HT29 cell line samples. Sample separation
over time,while PC2 separates samples due to different treatments. Reproducibility of the
Fig. 2.Hypergeometric test for biological processes enrichment. Hypergeometric test for biological processes enrichment of genes differentially regulated between all PLX4720 treatment
and control samples in both Colo-205 and HT29 cells (FDR corrected p-value b 0.001, moderated F-test). GO terms related to differentiation and development are marked in bold. Terms
related to metabolism are not considered for clarity. p-Value cutoff for the enrichment p b 0.01.
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8/10 relative to day 1.We tested for changes in a gene set in the same
direction using the per gene fold change and summarizing individual
p-values using Stouffer's method. Not surprisingly, GAGE conﬁrmed
the reduction of stemness with time (Fig. 3C) in both cell lines with a
more signiﬁcant effect in the Colo-205 cells.A B
C
Fig. 3. PLX4720 induces loss of stemness in Colo-205 andHT29. (A) Principal component analysi
component separates the samples according to their gene set expression. The cell line names are
at the bottom. (B) Boxplot of the scaled expression of the PluriNet marker genes. Median gen
stemness of the treated cell lines estimated by gene set enrichment of the PluriNet gene set t
differentiation marker genes for Colo-205 and HT29 cell lines.Discussion
We described analysis on the two colon cancer cell lines that harbor
BRAFV600Emutations. To elucidate the effect of thismutation on carcino-
genesis we compared the changes in gene expression of Colo-205 and
HT29 3D cultures under B-RAF inhibition over time. While the cellD
s of all NCI-60 cell lines based on the PluriNetmarker genes for stemness. Theﬁrst principal
color coded according to their tissue origin. The cell lines used in this paper are highlighted
e expression and therefore stemness increase from left to right. (C) Signiﬁcance of loss of
aking the PLX4720 treatment at day 1 as reference. (D) Fold change in the expression of
161M. Boerries et al. / Genomics Data 4 (2015) 158–161culture data indicated a high reproducibility, technical and/or biological
batch effects hindered us from direct comparison of the cell line data.
Therefore, we had to analyze each cell type individually. Yet, functional
enrichment of the gene expression clearly correlated with the treat-
ment and cell culture phenotype and suggested the restoration of differ-
entiated epithelia. The analysis predicted novel players involved in the
differentiation process and inversely suggested stemness properties
inherent in the cancer cell lines. Including a broader data base from
the NCI60 cell line panel allowed quantifying the relative differentiation
status of the cells. Gene set enrichment then demonstrated the loss of
stemness under B-RAF inhibition in line with the observed differentia-
tion phenotype. Based on Fig. 3C, it is even tempting to speculate that
the Colo-205 cells lose their stemness faster than HT29, as the latter
are more differentiated than the former according to Fig. 3B. This is
further supported by the stronger up-regulation over time of differenti-
ationmarkers in Colo-205 that are not part of the PluriNet gene set, e.g.,
the transcription factors Caudal TypeHomeobox 1 and 2 (Fig. 3D) or the
various gene products associated with epithelial differentiation and
effector functions [1].
In conclusion, we demonstrated the use of functional analysis in
combination with public database data to elucidate the oncogenic
mechanisms underlying BRAF mutations in Colon cancer that led to
the discovery of novel players and novel therapeutic rationales for
using pathway inhibitors in the treatment of this disease.Acknowledgment
All authors acknowledge ﬁnancial support by the DFG funded SFB
850 (projects B4 and Z1). We thank the microarray unit of the DKFZ
Genomics and Proteomics Core Facility for providing the Illumina
Whole-Genome Expression BeadChips and related services.References
[1] R. Herr, M. Köhler, H. Andrlová, F. Weinberg, Y. Möller, S. Halbach, et al., B-Raf inhib-
itors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. Cancer
Res. 75 (2015) 216–229, http://dx.doi.org/10.1158/0008-5472.CAN-13-3686.
[2] T.U. Semple, L.A. Quinn, L.K. Woods, G.E. Moore, Tumor and lymphoid cell lines from
a patient with carcinoma of the colon for a cytotoxicity model. Cancer Res. 38
(1978) 1345–1355.
[3] J. Fogh, G. Trempe, NewHuman Tumor Cell Lines. in: J. Fogh (Ed.), Hum. Tumor Cells
Vitro, Springer, US 1975, pp. 115–159 (http://link.springer.com/chapter/10.1007/
978-1-4757-1647-4_5 (accessed April 3, 2015)).
[4] M. Röring, R. Herr, G.J. Fiala, K. Heilmann, S. Braun, A.E. Eisenhardt, et al., Distinct re-
quirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf
signalling. EMBO J. 31 (2012) 2629–2647, http://dx.doi.org/10.1038/emboj.2012.
100.
[5] M. Dunning, A. Lynch, M. Eldridge, illuminaHumanv4.db: Illumina HumanHT12v4
annotation data (chip illuminaHumanv4), R package version 1.26.0.
[6] R. Gentleman, V. Carey, W. Huber, F. Hahne, geneﬁlter: geneﬁlter: methods for
ﬁltering genes from high-throughput experiments, R package version 1.50.0.
[7] D.W. Roberts, labdsv: ordination and multivariate analysis for ecology. http://CRAN.
R-project.org/package=labdsv2013.
[8] G.K. Smyth, Limma: linear models for microarray data. in: R. Gentleman, V. Carey, S.
Dudoit, R. Irizarry, W. Huber (Eds.),Bioinforma. Comput. Biol. Solut. Using R
BioconductorSpringer, New York 2005, pp. 397–420.
[9] S. Falcon, R. Gentleman, Using GOstats to test gene lists for GO term association.
Bioinform. Oxf. Engl. 23 (2007) 257–258, http://dx.doi.org/10.1093/bioinformatics/
btl567.
[10] F.-J. Müller, L.C. Laurent, D. Kostka, I. Ulitsky, R. Williams, C. Lu, et al., Regulatory net-
works deﬁne phenotypic classes of human stem cell lines. Nature 455 (2008)
401–405, http://dx.doi.org/10.1038/nature07213.
[11] R.H. Shoemaker, The NCI60 human tumour cell line anticancer drug screen. Nat. Rev.
Cancer 6 (2006) 813–823, http://dx.doi.org/10.1038/nrc1951.
[12] L. Gautier, L. Cope, B.M. Bolstad, R.A. Irizarry, affy—analysis of Affymetrix GeneChip
data at the probe level. Bioinform. Oxf. Engl. 20 (2004) 307–315, http://dx.doi.org/
10.1093/bioinformatics/btg405.
[13] M.Dai, P.Wang, A.D. Boyd, G. Kostov, B. Athey, E.G. Jones, et al., Evolving gene/transcript
deﬁnitions signiﬁcantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33
(2005)http://dx.doi.org/10.1093/nar/gni179 e175.
[14] W. Luo, M.S. Friedman, K. Shedden, K.D. Hankenson, P.J. Woolf, GAGE: generally
applicable gene set enrichment for pathway analysis. BMC Bioinform. 10 (2009)
161, http://dx.doi.org/10.1186/1471-2105-10-161.
